CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY.
Androgen Deprivation Therapy (ADT)
Cardiovascular Diseases
Myocardial Infarction
Prostate Cancer
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
3
1
2022
pubmed:
1
11
2019
medline:
1
11
2019
Statut:
ppublish
Résumé
The leading cause of death in patients with prostate cancer are cardiovascular diseases. Androgen deprivation therapy is the mainstay of treatment in prostate cancers. The latter has numerous perplexed disadvantaging effects to cardiovascular health. ADT alternates the metabolic profile, insulin resistance and glucose metabolism, causes loss of lean body mass, an increase in adipose tissue, obesity, worsening of atherosclerosis and heart failure. It is important to point out that prostate cancer survivors have increased prevalence of coronary artery disease, cerebrovascular stroke, myocardial infarctions and cardiovascular mortality. Due to these reasons particular care on prevention and treatment of cardiovascular diseases should become a standard of care in patients with prostate cancer.
Identifiants
pubmed: 34975199
doi: 10.20471/acc.2019.58.s2.09
pii: acc-58-supl-2-60
pmc: PMC8693560
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-63Références
Front Oncol. 2018 Nov 27;8:543
pubmed: 30538951
Hormones (Athens). 2017 Apr;16(2):115-123
pubmed: 28742500
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):333-339
pubmed: 27595915
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
BJU Int. 2013 Apr;111(4):543-8
pubmed: 23351025
J Clin Pharmacol. 2019 Mar;59(3):335-343
pubmed: 30402905
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Urology. 2008 Feb;71(2):318-22
pubmed: 18308111
JAMA. 2011 Dec 7;306(21):2359-66
pubmed: 22147380
J Clin Oncol. 2007 Jun 10;25(17):2420-5
pubmed: 17557956
Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):522-532
pubmed: 31303009
Support Care Cancer. 2019 Dec;27(12):4763-4770
pubmed: 30969369
Eur Urol. 2014 Apr;65(4):816-24
pubmed: 23453420
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46
pubmed: 19996060
Cancer. 2008 May 15;112(10):2188-94
pubmed: 18348297
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):112-115
pubmed: 30099132
Eur Urol. 2012 Jun;61(6):1119-28
pubmed: 22336376
J Clin Oncol. 2009 Jan 1;27(1):92-9
pubmed: 19047297
JAMA. 2009 Aug 26;302(8):866-73
pubmed: 19706860
Obes Rev. 2018 Jul;19(7):1008-1016
pubmed: 29573216
J Endocr Soc. 2018 Apr 20;2(5):485-496
pubmed: 29761176
Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1519-1527
pubmed: 29853568
Cancer. 2007 Oct 1;110(7):1493-500
pubmed: 17657815
Cancer. 2008 Dec 15;113(12):3290-7
pubmed: 18980297
Eur Urol. 2016 Feb;69(2):204-10
pubmed: 26362090
J Am Geriatr Soc. 2009 Jan;57(1):24-30
pubmed: 19054189
Urology. 2016 Nov;97:145-152
pubmed: 27502032
J Clin Endocrinol Metab. 2001 Sep;86(9):4261-7
pubmed: 11549659
Circulation. 2010 Feb 16;121(6):833-40
pubmed: 20124128
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Clin Oncol. 2017 Nov 10;35(32):3697-3705
pubmed: 28968166
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
pubmed: 11836291
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
Curr Oncol Rep. 2019 Aug 24;21(10):91
pubmed: 31446509